Novartis Reports Results of Kesimpta (ofatumumab) in P-IIIb (ALITHIOS) OLE Study for the Treatment of Multiple Sclerosis
Shots:
- The P-IIIb (ALITHIOS) OLE study evaluates ofatumumab in 1969 patients with RMS who have participated in ofatumumab clinical MS study
- The results showed no evidence of an increase in the incidence of sev. outcomes in COVID-19 inf., mean IgG levels remained stable @~3.5yrs. & IgM levels remained above the lower limit of normal, overall incidence of serious inf. was low with no new safety risks & no incidences of opportunistic inf. were reported. The results were published in the peer-reviewed Multiple Sclerosis Journal
- The therapy showed a superior efficacy with similar safety & tolerability profile. Kesimpta is a targeted B-cell therapy & provides the flexibility of self-administration for RMS
Ref: Novartis | Image: Novartis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
